DLD

DLD encodes dihydrolipoamide dehydrogenase, the shared E3 flavoenzyme subunit common to four mitochondrial multienzyme complexes—pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase (KGDC), branched-chain alpha-ketoacid dehydrogenase, and the glycine cleavage system—as established genetically by murine knockout: complete loss causes perigastrulation embryonic lethality, while heterozygotes show coordinate ~50% reduction in E3 activity across all four complexes (PMID:9405644). Through this E3 activity DLD contributes to pyruvate decarboxylation, TCA-cycle flux, and mitochondrial ATP production, and its loss in cancer cells lowers the NAD+/NADH ratio and suppresses proliferation, linking the enzyme to cellular redox and metabolic balance (PMID:37123026). The protein interacts with partner E2 subunits and the E3-binding protein through an interface domain, and missense mutations clustering in this region (p.R482G, near p.D479V) can selectively impair KGDC, indicating that E3's engagement of its partner complexes is not uniform (PMID:15712224). In humans, hypomorphic DLD mutations causing reduced E3 activity produce dihydrolipoamide dehydrogenase deficiency presenting as Leigh syndrome with episodic encephalopathy and lactic ketoacidosis (PMID:23290025). The gene is transcriptionally configured for mitochondrial/respiratory function, with promoter elements including an NRF1 site (PMID:8406489).

1. 1993 Medium

   Before its regulation was understood, the genomic organization and promoter architecture of human DLD were undefined; mapping the gene established how this housekeeping mitochondrial enzyme is transcriptionally controlled.

   Evidence Restriction mapping, genomic sequencing, and primer extension of the human DLD locus

   PMID:8406489

   Open questions at the time

   • Functional activity of the identified NRF1/Sp1/CRE elements not tested by reporter assays
   • Does not address protein function or enzymatic mechanism
2. 1997 High

   It was unclear whether a single E3 subunit served all dihydrolipoamide-dependent complexes; knockout established DLD as the obligate shared E3 for four mitochondrial complexes and as essential for embryogenesis.

   Evidence Homologous-recombination knockout in mice with enzymatic assays of E3 and all four complexes

   PMID:9405644

   Open questions at the time

   • Embryonic lethality precludes analysis of tissue-specific roles
   • Does not resolve how one E3 is shared among structurally distinct complexes
3. 2005 Medium

   Whether E3 interacts identically with each partner complex was unknown; an interface-domain mutation causing isolated KGDC deficiency showed E3-partner interactions differ among complexes.

   Evidence Enzyme assays and DLD sequencing in patient fibroblasts identifying p.R482G in the E2/E3-binding interface

   PMID:15712224

   Open questions at the time

   • Mechanism of selective KGDC impairment inferred from mutation location, not structurally resolved
   • Differential binding affinities not measured directly
4. 2013 Medium

   The clinical range of DLD deficiency was incompletely defined; compound-heterozygous patients extended the spectrum to include Leigh syndrome.

   Evidence Enzymatic and molecular diagnosis in fibroblasts with metabolite profiling during decompensation

   PMID:23290025

   Open questions at the time

   • Single patient; genotype-phenotype correlation not generalized
   • Does not establish why residual E3 activity yields Leigh-type neuropathology
5. 2019 Low

   Beyond catalysis, DLD's contribution to redox state was synthesized into a framework casting it as a bidirectional modulator of ROS/RNS and a possible oxidative-stress target.

   Evidence Review synthesis of prior inhibitor and mechanistic studies

   PMID:30717346

   Open questions at the time

   • Review without new primary data
   • Conditions determining ROS enhancement vs attenuation not defined experimentally here
6. 2020 Medium

   Whether reducing DLD activity has consequences beyond ATP loss was open; ortholog suppression in a C. elegans Abeta model conferred protection distinct from a metabolic uncoupler.

   Evidence RNAi of dld-1 in Abeta worms with behavioral assays, Abeta-oligomer quantification, proteomics, and FCCP comparator

   PMID:34522713

   Open questions at the time

   • Mechanism linking dld-1 loss to reduced Abeta oligomerization unresolved
   • Findings in worm ortholog not validated in mammalian neurons
7. 2021 Low

   DLD's potential involvement in transcriptional and ferroptosis circuitry was probed; it was identified as a CLTRN-interacting protein within a proposed NRF1/RAN/DLD complex linked to glutathione metabolism.

   Evidence Co-immunoprecipitation, RNA-seq, and ferroptosis-marker assays in HCC cells

   PMID:33508374

   Open questions at the time

   • Single Co-IP without reciprocal validation for DLD
   • DLD's specific contribution to the complex's regulatory activity not directly tested
8. 2023 Low

   DLD's role in cancer metabolism was tested; knockdown lowered the NAD+/NADH ratio and suppressed proliferation, tying it to TCA-cycle flux in tumor cells.

   Evidence siRNA knockdown with NAD+/NADH measurement and proliferation assay in ovarian cancer cells

   PMID:37123026

   Open questions at the time

   • Single knockdown experiment without rescue
   • Downstream effectors linking NAD+/NADH change to proliferation not identified

• How E3/DLD switches between enhancing and attenuating ROS, and how its interface selectively engages distinct partner complexes, remains mechanistically unresolved.
• No structural model of complex-specific E3 docking in the timeline
• Causal, redox-state-resolved control of ROS by DLD not established